TVTX News
Travere to Present New Data Supporting FILSPARI (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI...
Business Wire
Travere to Present New Data Supporting FILSPARI (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI...
Business Wire
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmPR NewswireNEW YORK, Sept. 30, 2026NEW YORK, Sept. 30, 2026/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sparsentan) in Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders, directed to certain...
Business Wire
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Companys Board of Directors has unanimously appointed Bradley L. Campbell...
Business Wire
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Traveres website...
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 56,220 shares of its...
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 38,940 shares of its...
Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conference Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET Wells Fargo 21st Annual Healthcare Conference...
Business Wire
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On
Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.read more...
Benzinga
Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks